Literature DB >> 2319807

Human B lymphocytes express the p75 component of the interleukin 2 receptor.

C G Begley1, J D Burton, M Tsudo, B H Brownstein, J L Ambrus, T A Waldmann.   

Abstract

The nature of the interleukin 2 (IL-2) receptor on purified human B lymphocytes was examined. Both normal and malignant cells showed evidence of a 70-75,000 mol. wt (p75) IL-2 binding molecule as assessed by 125I-labeled IL-2 binding and receptor cross-linking. On normal, Tac-negative B lymphocytes the estimated number of p75 binding sites was 1100 per cell and the dissociation constant (Kd) was 1.7 nM. Consistent with this, cross-linking experiments demonstrated the presence of an IL-2 binding molecule of 70-75,000 mol. wt. Purified B cells from patients with hairy cell leukemia and chronic lymphocytic leukemia (CLL) also expressed the p75 IL-2 binding molecule. In the HCL samples, a small number of high-affinity IL-2 binding sites were detected (27-90) while the majority of binding sites (2100-10,800) were typical of low-affinity p55 Tac binding. IL-2 added to the purified normal and CLL B lymphocytes led to the induction of p55 Tac expression and the generation of high-affinity IL-2 receptors. This response to IL-2 was equivalent to the response observed when normal B lymphocytes were stimulated by Staphylococcus aureus Cowan I.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2319807     DOI: 10.1016/0145-2126(90)90134-u

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  The immediate-early gene product Egr-1 regulates the human interleukin-2 receptor beta-chain promoter through noncanonical Egr and Sp1 binding sites.

Authors:  J X Lin; W J Leonard
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

Review 2.  Optimizing tumor immune response through combination of radiation and immunotherapy.

Authors:  Alissar El Chediak; Ali Shamseddine; Larry Bodgi; Jean-Pierre Obeid; Fady Geara; Youssef H Zeidan
Journal:  Med Oncol       Date:  2017-08-21       Impact factor: 3.064

3.  The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

Authors:  R N Bamford; A J Grant; J D Burton; C Peters; G Kurys; C K Goldman; J Brennan; E Roessler; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

4.  Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain.

Authors:  H Suzuki; G S Duncan; H Takimoto; T W Mak
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

5.  Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes.

Authors:  A C Fluckiger; P Garrone; I Durand; J P Galizzi; J Banchereau
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

6.  Cytokines in cancer immunotherapy.

Authors:  Sylvia Lee; Kim Margolin
Journal:  Cancers (Basel)       Date:  2011-10-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.